Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.

评价LT-002-158片在中重度化脓性汗腺炎患者中的安全性和耐受性,疗效和药代动力学特征。

评价LT-002-158片在中重度特应性皮炎受试者中的安全性和耐受性，初步有效性和药代动力学特征。

This study is a Phase Ic/II clinical trial conducted in Chinese patients with moderate-to-severe hidradenitis suppurativa (HS), aiming to evaluate the safety and efficacy of LT-002-158 tablets in the treatment of moderate-to-severe HS.
The study consists of two parts. The Phase Ic portion employs an open-label, single-arm design to primarily investigate the safety and tolerability of LT-002-158 tablets in patients with moderate-to-severe HS. The Phase II study adopts a randomized, double-blind, placebo-controlled, parallel-group design, with an open-label, single-arm extension phase, to primarily assess the therapeutic efficacy of LT-002-158 tablets in patients with moderate-to-severe HS.